AU2018386193B2 - FcRn antibodies and methods of use thereof - Google Patents

FcRn antibodies and methods of use thereof Download PDF

Info

Publication number
AU2018386193B2
AU2018386193B2 AU2018386193A AU2018386193A AU2018386193B2 AU 2018386193 B2 AU2018386193 B2 AU 2018386193B2 AU 2018386193 A AU2018386193 A AU 2018386193A AU 2018386193 A AU2018386193 A AU 2018386193A AU 2018386193 B2 AU2018386193 B2 AU 2018386193B2
Authority
AU
Australia
Prior art keywords
seq
sequence
antibody
fcrn
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018386193A
Other languages
English (en)
Other versions
AU2018386193A8 (en
AU2018386193A1 (en
Inventor
Nicholas A. CILFONE
Leona E. Ling
Darrell NIX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of AU2018386193A1 publication Critical patent/AU2018386193A1/en
Publication of AU2018386193A8 publication Critical patent/AU2018386193A8/en
Application granted granted Critical
Publication of AU2018386193B2 publication Critical patent/AU2018386193B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2018386193A 2017-12-13 2018-12-13 FcRn antibodies and methods of use thereof Active AU2018386193B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598402P 2017-12-13 2017-12-13
US62/598,402 2017-12-13
US201862701354P 2018-07-20 2018-07-20
US62/701,354 2018-07-20
PCT/US2018/065568 WO2019118791A1 (en) 2017-12-13 2018-12-13 Fcrn antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2018386193A1 AU2018386193A1 (en) 2020-06-25
AU2018386193A8 AU2018386193A8 (en) 2020-07-02
AU2018386193B2 true AU2018386193B2 (en) 2025-04-24

Family

ID=65041911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018386193A Active AU2018386193B2 (en) 2017-12-13 2018-12-13 FcRn antibodies and methods of use thereof

Country Status (12)

Country Link
US (2) US11773168B2 (https=)
EP (1) EP3723802A1 (https=)
JP (3) JP7420720B2 (https=)
KR (2) KR102904658B1 (https=)
CN (1) CN111712259A (https=)
AU (1) AU2018386193B2 (https=)
BR (1) BR112020011310A2 (https=)
CA (1) CA3085751A1 (https=)
IL (1) IL275070A (https=)
NZ (1) NZ765250A (https=)
SG (1) SG11202005021PA (https=)
WO (1) WO2019118791A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
AU2021292200A1 (en) * 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
US20240182598A1 (en) * 2021-04-12 2024-06-06 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
CN116234827A (zh) * 2021-09-03 2023-06-06 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用
KR20240134900A (ko) * 2022-01-17 2024-09-10 아르젠엑스 비브이 자가항체 매개 질환 환자를 치료하기 위한 방법
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
CN121909214A (zh) 2023-07-31 2026-04-21 玫帝托克斯股份有限公司 一种抗体及包含该抗体的用于治疗免疫疾病的药物组合物
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123521A2 (en) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
ES2765874T3 (es) * 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
PL3137504T3 (pl) 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
EP3294335B1 (en) * 2015-05-12 2023-07-05 Syntimmune Inc. Humanized affinity matured anti-fcrn antibodies
JP6913527B2 (ja) 2017-06-22 2021-08-04 株式会社小松製作所 油圧ポンプおよびモータ
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
WO2019160979A1 (en) 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
WO2020023310A1 (en) 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
EP4007605A4 (en) 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
IL302516A (en) 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123521A2 (en) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI CONGLEI ET AL 2011: "The maternal immune response to fetal platelet GPIb alpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies", J. CLINICAL INVESTIGATION, v. 121, no. 11, p. 4537-47 *

Also Published As

Publication number Publication date
KR102904658B1 (ko) 2025-12-29
AU2018386193A8 (en) 2020-07-02
CA3085751A1 (en) 2019-06-20
JP2021506786A (ja) 2021-02-22
CN111712259A (zh) 2020-09-25
JP2024016042A (ja) 2024-02-06
US11773168B2 (en) 2023-10-03
SG11202005021PA (en) 2020-07-29
JP2025143252A (ja) 2025-10-01
US20220064290A1 (en) 2022-03-03
JP7420720B2 (ja) 2024-01-23
US20240158509A1 (en) 2024-05-16
KR20200098604A (ko) 2020-08-20
WO2019118791A1 (en) 2019-06-20
EP3723802A1 (en) 2020-10-21
AU2018386193A1 (en) 2020-06-25
JP7690538B2 (ja) 2025-06-10
KR20260008175A (ko) 2026-01-15
IL275070A (en) 2020-07-30
NZ765250A (en) 2026-02-27
BR112020011310A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
US20240158509A1 (en) Fcrn antibodies and methods of use thereof
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
HK40104376A (en) Fcrn antibodies and methods of use thereof
HK40002836B (en) Fcrn antibodies and methods of use thereof
HK40002836A (en) Fcrn antibodies and methods of use thereof
CA2972822C (en) Fcrn antibodies and methods of use thereof
BR122025025099A2 (pt) Anticorpos contra fcrn, usos dos mesmos e composições

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 25 , PAGE(S) 3479 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MOMENTA PHARMACEUTICALS, INC., APPLICATION NO. 2018386193, UNDER INID (72) ADD CO-INVENTOR LING, LEONA E.; CILFONE, NICHOLAS A

FGA Letters patent sealed or granted (standard patent)